<DOC>
	<DOCNO>NCT02381275</DOCNO>
	<brief_summary>Lighthouse , cooperation University Heidelberg Public Health Institute University KÃ¶ln ( Cologne ) would like set cohort study baseline characteristic long-term clinical outcome patient use Tenofovir base Antiretroviral Therapy Lighthouse . As March 2014 , patient 18 year give informed consent come Lighthouse newly initiate ART approach enroll cohort . The result disseminate nationally Ministry Health Technical Working Group ( TWG ) , annual Research Dissemination Best Practices conferences College Medicine National AIDS Commission well internationally . The result also write publication appropriate peer-reviewed journal .</brief_summary>
	<brief_title>The Lighthouse Tenofovir Cohort Study</brief_title>
	<detailed_description>The propose observational cohort study lead improve identification patient virological failure adverse drug effect , improve identification relevant co-morbidities result well individual management . More importantly however , result allow estimate proportion describe complication overall Malawian treatment cohort . This claim exemplify retrospective analysis patient Lighthouse switch new 5A regimen 6 A regimen result adverse effect Efavirenz . The aim study describe baseline clinical characteristic long-term outcome patient use Tenofovir base antiretroviral therapy Lighthouse Clinics . The specific objective outline : Objective 1 : To determine prevalence renal dysfunction enrolment follow-up among adult HIV-infected individual start ART . Objective 2 : To determine prevalence Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) infection among adult HIV-infected individual start ART treatment follow-up . Objective 3 : To determine prevalence non-communicable co-morbidities treatment follow-up HIV-infected individual start ARTand treatment follow-up . The study take place Lighthouse , tertiary referral ART centre , 25,000 patient , Lilongwe , Malawi . Considering study cost power detect prevalence 22 % renal impairment , expect convenience sample size least 850 patient end three year follow-up period . The current retention three year almost 56 % . Using retention , therefore enrol almost 1,500 patient start ART .</detailed_description>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>18 year older Able willing give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>